LAWRENCE, RONNIE MAXWELL,ARET, EDWIN,BORTHWICK, ALAN DAVID,BROWN, JANE THERESA,CORCORAN, JONATHAN PATRICK THOMAS,DE CASTRO VASCONCELOS GONCALVES, MARIA BEATRIZ,KALINDJIAN, SARKIS BARRET
申请号：
CA3025858
公开号：
CA3025858A1
申请日:
2017.06.16
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (referred to herein as "BHBA-001"), which, inter alia, is a (selective) retinoic acid receptor beta (RARß) (e.g., RARß2) agonist. The present invention also pertains to pharmaceutical compositions comprising such crystalline forms, and the use of such crystalline forms and compositions, both in vitro and in vivo, to (selectively) activate RARß (e.g., RARß2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARß (e.g., RARß2), that are ameliorated by the activation of RARß (e.g., RARß2), etc., including, e.g., neurological injuries such as spinal cord injuries.
